4.6 Article

BI-2536 Promotes Neuroblastoma Cell Death via Minichromosome Maintenance Complex Components 2 and 10

Journal

PHARMACEUTICALS
Volume 15, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/ph15010037

Keywords

minichromosome maintenance complex 2 and 10; BI-2536; neuroblastoma; mitochondria fusion; cell death

Funding

  1. Ministry of Science and Technology in Taiwan [MOST 109-2327-B-006-004, MOST 109-2320-B-002-017-MY3, MOST 109-2221-E-002-161-MY3, MOST 109-2221-E-010-012-MY3, MOST 109-2221-E-010-011-MY3]
  2. The Higher Education Sprout Project [110L8808, NTU-CC-109L104702-2]
  3. NTU Hospital [UN110-003]

Ask authors/readers for more resources

This study discovers the correlation between high levels of MCM2 and MCM10 and poor survival rate in neuroblastoma patients. The drug BI-2536 can inhibit the expression of MCM2 and MCM10, promoting mitochondrial fusion, G2/M arrest, and apoptosis, providing a new strategy for neuroblastoma therapy.
DNA replication is initiated with the recognition of the starting point of multiple replication forks by the origin recognition complex and activation of the minichromosome maintenance complex 10 (MCM10). Subsequently, DNA helicase, consisting of the MCM protein subunits MCM2-7, unwinds double-stranded DNA and DNA synthesis begins. In previous studies, replication factors have been used as clinical targets in cancer therapy. The results showed that MCM2 could be a proliferation marker for numerous types of malignant cancer. We analyzed samples obtained from patients with neuroblastoma, revealing that higher levels of MCM2 and MCM10 mRNA were associated with poor survival rate. Furthermore, we combined the results of the perturbation-induced reversal effects on the expression levels of MCM2 and MCM10 and the sensitivity correlation between perturbations and MCM2 and MCM10 from the Cancer Therapeutics Response Portal database. Small molecule BI-2536, a polo-like kinase 1 (PLK-1) inhibitor, is a candidate for the inhibition of MCM2 and MCM10 expression. To test this hypothesis, we treated neuroblastoma cells with BI-2536. The results showed that the drug decreased cell viability and reduced the expression levels of MCM2 and MCM10. Functional analysis further revealed enrichments of gene sets involved in mitochondria, cell cycle, and DNA replication for BI-2536-perturbed transcriptome. We used cellular assays to demonstrate that BI-2536 promoted mitochondria fusion, G2/M arrest, and apoptosis. In summary, our findings provide a new strategy for neuroblastoma therapy with BI-2536.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available